Provide feedbackProvide feedback
Home :: Women's Health

PPI use not associated with hip fractures in postmenopausal women; modest association found for other fractures, study reveals

Wednesday, May 19 2010 | Comments
Evidence Grade 2 What's This?

Among postmenopausal women, proton pump inhibitor (PPI) use does not appear to be associated with hip fractures, new data indicate, although use of these agents is modestly associated with clinical spine, forearm or wrist, and total fractures. Researchers conducted a prospective analysis of 161,806 postmenopausal women aged 50 to 79 years. The participants had no history of hip fracture and had been enrolled in the Women's Health Initiative observational study and clinical trials. The...

Among postmenopausal women, proton pump inhibitor (PPI) use does not appear to be associated with hip fractures, new data indicate, although use of these agents is modestly associated with clinical spine, forearm or wrist, and total fractures.

Researchers conducted a prospective analysis of 161,806 postmenopausal women aged 50 to 79 years. The participants had no history of hip fracture and had been enrolled in the Women's Health Initiative observational study and clinical trials. The investigators obtained data regarding the patients' medication use during in-person interviews at baseline and at 3 years. Complete information was available for 130,487 women. Mean follow-up was 7.8 years.

The study's primary outcome measure was self-reported fractures (hip, clinical spine, forearm or wrist, and total fractures). In a subsample of nearly 7,000 patients, the primary outcome measure also included 3-year change in bone mineral density (BMD).

The annualized rate of hip fractures was 0.15% for nonusers and 0.19% for PPI users. Data from the fully adjusted models indicated that PPI use was not related to an increased risk of hip fracture (HR, 1.00; 95% CI, 0.71-1.40) but was related to a significantly increased risk of clinical spine, forearm or wrist, and total fractures. Specifically, the women who used PPIs had a 47% increased risk of clinical spine fracture (HR, 1.47; 95% CI, 1.18-1.82), a 26% increased risk of forearm or wrist fractures (HR, 1.26; 95% CI, 1.05-1.51), and a 25% increased risk for total fractures (HR, 1.25; 95% CI, 1.15-1.36).

There was no difference in BMD measurements between the PPI users and nonusers at baseline. The 3-year change in BMD at the hip marginally favored no PPI use, although no difference was noted for BMD change at other sites between the PPI users and nonusers.

"Questions remain regarding the potential risk associated with long-term PPI use and fracture risk; thus, based on the accumulation of evidence, it is prudent for clinicians to periodically reevaluate the need for long-term PPI therapy," the authors concluded. "For those older adults who do require long-term PPI therapy, it is reasonable to focus on using the lowest effective dose, ensuring adequate dietary calcium intake, and adding calcium supplements when necessary." (Gray SL, et al. Arch Intern Med 2010;170:765-771.)

Latest News

Trial fails to show benefit of vitamins C, E to reduce complications of pregnancy-associated hypertension in low-risk women Verusmed

Tuesday, April 13 2010 | Comments
Evidence Grade 1 What's This?
Among low-risk, nulliparous women, supplementation with vitamins C and E during pregnancy does not reduce rates of adverse maternal or perinatal outcomes resulting from pregnancy-associated hypertension, according to findings from a large, randomized, double-blind, placebo-controlled trial.

Researchers randomized 10,154 nulliparous women with a low risk for preeclampsia to receive a supplement containing 1,000 mg/day of vitamin C and 400 IU/d of vitamin E or matching placebo,...

Women have higher rate of early CRC after negative colonoscopy, data suggest, possibly because of greater burden of missed proximal lesions at screening Verusmed

Wednesday, March 24 2010 | Comments
Evidence Grade 3 What's This?
A negative colonoscopy is associated with a reduced short-term risk of colorectal cancer (CRC) in men but not in women, according to findings from a study conducted in Manitoba, Canada. According to the study data, this discrepancy might be the result of a higher incidence of proximal CRC cases in women, which are more likely to be missed by colonoscopists during screening.

Researchers reviewed data for 45,985 individuals (women, n=27,379) aged 40 years or older who were...


Paroxetine interferes with clinical benefit of tamoxifen therapy, research indicates Verusmed

Friday, February 19 2010 | Comments
Evidence Grade 2 What's This?
Women with breast cancer who take paroxetine hydrochloride, a selective serotonin uptake inhibitor (SSRI) antidepressant, concomitantly with tamoxifen, a selective estrogen receptor modulator, appear to be more likely to die from the disease than are women who take other SSRIs, according to recently published study results.

Cytochrome P450 isoenzyme 2D6 (CYP2D6) is the primary catalyst that converts the prodrug tamoxifen to the active metabolite endoxifen, which has an affinity...
Tags: Breast Cancer


Data indicate potential favorable long-term effect of childbirth on MS course Verusmed

Wednesday, February 03 2010 | Comments
Evidence Grade 3 What's This?
Among women with multiple sclerosis (MS), those who have children--particularly those who have children after MS onset--seem to experience a more benign disease course relative to women who do not give birth, study results indicate.

Researchers evaluated the long-term effects of childbirth in 330 women with MS; the mean duration of MS was 17.7 years, and 55% of the women had an Expanded Disability Status Scale (EDSS) score of >=6. Of these women, 80 had no children, 170 had...
Tags: Multiple Sclerosis